KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $11.4 billion.

  • Jazz Pharmaceuticals' Liabilities and Shareholders Equity fell 733.72% to $11.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 billion, marking a year-over-year decrease of 105.84%. This contributed to the annual value of $12.0 billion for FY2024, which is 543.21% up from last year.
  • Jazz Pharmaceuticals' Liabilities and Shareholders Equity amounted to $11.4 billion in Q3 2025, which was down 733.72% from $10.9 billion recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Liabilities and Shareholders Equity peaked at $13.2 billion during Q2 2021, and registered a low of $6.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $11.4 billion (2025), whereas its average is $11.3 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Liabilities and Shareholders Equity soared by 11780.25% in 2021, and later tumbled by 1677.72% in 2022.
  • Jazz Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $12.3 billion in 2021, then fell by 11.9% to $10.8 billion in 2022, then grew by 5.15% to $11.4 billion in 2023, then grew by 5.43% to $12.0 billion in 2024, then dropped by 5.46% to $11.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $11.4 billion in Q3 2025, compared to $10.9 billion in Q2 2025 and $11.5 billion in Q1 2025.